Literature DB >> 23823132

Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia.

Alejandro Ballesteros1, Ann Summerfelt, Xiaoming Du, Pan Jiang, Joshua Chiappelli, Malle Tagamets, Patricio O'Donnell, Peter Kochunov, L Elliot Hong.   

Abstract

OBJECTIVE: Diverse electrophysiological abnormalities have been associated with schizophrenia, but the underlying causes remain elusive. We tested whether the altered oxidative stress in schizophrenia contributes to the electrophysiological abnormalities.
METHODS: We used an auditory oddball task to measure mismatch negativity (MMN) and gamma band response on 29 schizophrenia patients and 25 normal controls. Oxidative stress was assessed by monomeric glutathione (GSH, reduced form) and glutathione disulfide (GSSG, oxidized form).
RESULTS: Patients had reduced MMN (p=0.015) and reduced power of gamma band responses at 21-40 Hz and 41-85 Hz (all p<0.001). GSH was significantly lower (p<0.001) while %GSSG was higher (p=0.023) in patients compared with controls. MMN was correlated with GSH in controls; while 21-40 Hz responses were correlated with GSH in patients. Lower GSH and higher GSSG levels were associated with low community functioning (p=0.018). Multivariate mediation modeling showed that gamma band at 21-40 Hz was a significant mediator for GSH effect on community functions.
CONCLUSIONS: High beta/low gamma range (21-40 Hz) responses may be an intermediate biomarker indexing oxidative stress and its effect on clinical functions. SIGNIFICANCE: Electrophysiological abnormalities and associated clinical functional changes may in part be associated with heightened oxidative stress in schizophrenia.
Copyright © 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  GSH; GSSG; MMN; Oscillations; Oxidation; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23823132      PMCID: PMC4030436          DOI: 10.1016/j.clinph.2013.05.021

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  62 in total

Review 1.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 2.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

3.  Induced gamma band responses in human EEG after the control of miniature saccadic artifacts.

Authors:  Uwe Hassler; Nelson Trujillo Barreto; Thomas Gruber
Journal:  Neuroimage       Date:  2011-05-30       Impact factor: 6.556

4.  Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia.

Authors:  Jeremy W Gawryluk; Jun-Feng Wang; Ana C Andreazza; Li Shao; Lakshmi N Yatham; L Trevor Young
Journal:  Int J Neuropsychopharmacol       Date:  2011-05-09       Impact factor: 5.176

5.  Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder.

Authors:  Anita Kulak; Michel Cuenod; Kim Q Do
Journal:  Behav Brain Res       Date:  2011-10-20       Impact factor: 3.332

Review 6.  Inhibitory interneurons, oxidative stress, and schizophrenia.

Authors:  Elyse M Sullivan; Patricio O'Donnell
Journal:  Schizophr Bull       Date:  2012-03-29       Impact factor: 9.306

7.  Fast reconfiguration of high-frequency brain networks in response to surprising changes in auditory input.

Authors:  Ruth M Nicol; Sandra C Chapman; Petra E Vértes; Pradeep J Nathan; Marie L Smith; Yury Shtyrov; Edward T Bullmore
Journal:  J Neurophysiol       Date:  2011-12-14       Impact factor: 2.714

8.  Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients.

Authors:  Monia Raffa; Fatma Atig; Ahmed Mhalla; Abdelhamid Kerkeni; Anwar Mechri
Journal:  BMC Psychiatry       Date:  2011-08-02       Impact factor: 3.630

9.  Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.

Authors:  Cristian Carmeli; Maria G Knyazeva; Michel Cuénod; Kim Q Do
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

10.  A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior.

Authors:  M Carlén; K Meletis; J H Siegle; J A Cardin; K Futai; D Vierling-Claassen; C Rühlmann; S R Jones; K Deisseroth; M Sheng; C I Moore; L-H Tsai
Journal:  Mol Psychiatry       Date:  2011-04-05       Impact factor: 15.992

View more
  8 in total

1.  Oxidative/Nitrosative stress in psychiatric disorders: are we there yet?

Authors:  Patricio O'Donnell; Kim Q Do; Celso Arango
Journal:  Schizophr Bull       Date:  2014-04-08       Impact factor: 9.306

2.  Microglia Activation in Subjects at Risk for Psychosis: Fact or Fiction?

Authors:  Patricio O'Donnell
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

3.  Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.

Authors:  Michael Avissar; Shanghong Xie; Blair Vail; Javier Lopez-Calderon; Yuanjia Wang; Daniel C Javitt
Journal:  Schizophr Res       Date:  2017-07-11       Impact factor: 4.939

4.  Event-related potential and time-frequency endophenotypes for schizophrenia and psychotic bipolar disorder.

Authors:  Lauren E Ethridge; Jordan P Hamm; Godfrey D Pearlson; Carol A Tamminga; John A Sweeney; Matcheri S Keshavan; Brett A Clementz
Journal:  Biol Psychiatry       Date:  2014-05-04       Impact factor: 13.382

Review 5.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

6.  Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.

Authors:  Maju Mathew Koola; Samir Kumar Praharaj; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2019-05-17

Review 7.  Accelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species.

Authors:  Priscila Britto Campos; Bruna S Paulsen; Stevens K Rehen
Journal:  Front Aging Neurosci       Date:  2014-10-27       Impact factor: 5.750

8.  Dysregulation of amino acids and lipids metabolism in schizophrenia with violence.

Authors:  Xiacan Chen; Jiajun Xu; Jing Tang; Xinhua Dai; Haolan Huang; Ruochen Cao; Junmei Hu
Journal:  BMC Psychiatry       Date:  2020-03-04       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.